Abstract
<p>The aim of this meta-analysis was to systematically evaluate the efficacy and safety of novel oral anticoagulants and vitamin K antagonists in the treatment of venous thromboembolism. A total of 6 studies met the inclusion criteria and a total of 19,350 patients with venous thromboembolism were included. Among them, rivaroxaban (3 RCTs, n=90/3,449/4,832); dabigatran (2 RCTs, n=200/2,539); edoxaban (1 RCT, n=8,240). The results of meta-analysis showed that the total bleeding rate after treatment with the vitamin K antagonist group was higher than with the new oral anticoagulant group (OR=0.82, 95% confidence interval 0.75-0.90, p&lt;0.0001), and the difference was highly statistically significant. Overall, new oral anticoagulants are compara-ble to vitamin K antagonists, but new oral anticoagulants can reduce the occurrence of bleeding events and the safety was superior to vitamin K antagonists.</p>
Highlights
Venous thromboembolism refers to the abnormal coagulation of blood in the vein, causing partial or complete obstruction of the lumen
A total of 1,366 literature was preliminarily retrieved according to the above inclusion and exclusion criteria, 1,313 of them was excluded after reading the titles and abstracts, and the remaining 53 was downloaded and the full-texts were read. 47 out of these 53 literature was excluded, including 11 with irrelevant research objective, 23 reviews, conference papers and critical papers, 10 non-randomized controlled trials (RCTs) and 3 repetitive studies
The EINSTEIN Investigators and EINSTEIN-PE Investigators had compared the efficacy between deep venous thrombosis and pulmonary embolism patients, respectively
Summary
Venous thromboembolism refers to the abnormal coagulation of blood in the vein, causing partial or complete obstruction of the lumen. It includes deep venous thrombosis and pulmonary embolism, which are the manifestation forms of the same disease at different stages. It is frequently seen in long-term bedridden and perioperative complications. The early clinical confirmation of deep venous thrombosis and pulmonary embolism depends on the high understanding of clinicians and the public towards these diseases. It is necessary to more accurately identify patient associated with the risk of venous thromboembolism, and safe and effective preventive treatment are needed
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
